Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation

Conditions: BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Interventions: Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting Sponsors: Assistance Publique - H ôpitaux de Paris; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials